Cost and Benefit

Abstract

The cost of an individual assay may be calculated quite simplistically by the addition of cost for reagents and technical time, and if applicable, depreciable automation costs. Such estimates are usually inaccurate on a per specimen basis and true costs are influenced by many other variables. For example, the cost may be altered by the number of specimens to be run simultaneously. Some EIA assays may be formatted in such a way that excess reagent strips are required to be used for the few specimens that assessment. Repeat tests may have to be performed. The frequency of false positive assays given endemic seroprevalence, which may vary, will affect other investigative and interventionist strategies. Therefore, an inexpensive but very rapid serological assay could conceivably lead to considerable additional and unwarranted health care costs if indeed it is frequently inaccurate. Conversely, a more expensive serodiagnostic or PCR diagnostic could be acceptable if the information gained leads to an appropriate diagnosis and to improved management. Even if only measured by hospital days saved, a rapid diagnostic assay has the potential to impact greatly.